Please note: AABB reserves the right to make updates to this program.
Thursday, September 6, 2018
2:00 – 3:00 PM (ET) 7:00 – 8:00 PM (GMT)
Master Program Number: 18EL-360
Educational Track: Technical/Clinical
Topic: Cellular Therapies
Intended Audience: Director, Donor Recruitment Staff, Hospital Blood Banks, HR Personnel, Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Physicians, Research Scientists, Resident/Fellow, Scientists, Students (MD, MT, SBB), Technologists, General audience
Teaching Level: Basic
Director: Ed Brindle, MSc, MLT(CMLTO), Director Quality & Regulatory Affairs, Insception Lifebank, Mississauga, Ontario, Canada
Moderator: Missy Vogelpohl, MT(ASCP), MBA, Principal Clinical Affairs Specialist, ViaCord (From PerkinElmer), Hebron, KY
Speakers: Ed Brindle, MSc, MLT(CMLTO), Director Quality & Regulatory Affairs, Insception Lifebank, Ontario, Canada; Mike Halpenny, MLT(CMLTO), Manager, Cord Blood Bank & Stem Cell Manufacturing, Canadian Blood Services, Ottawa, Canada; Missy Vogelpohl, MT(ASCP), MBA, Principal Clinical Affairs Specialist, ViaCord (From PerkinElmer), Hebron, KY
This is a complimentary eCast.
Please register directly via GoToWebinar at
https://attendee.gotowebinar.com/register/3225390264000848898. After you register you will immediately receive a unique log in to access the eCast on the program date. Please click on the “Add to Calendar” link in the email to add this program to your calendar.
After participating in this educational activity, participants should be able to:
- Describe the processes of cord blood collection and manufacturing.
- Identify challenges to the cord blood industry.
- Discuss applications and clinical trials using cord blood.
- Interpret the current challenges and history to consider future directions of cord blood use.
2018 marks the 30-year anniversary of the first cord blood transplant. What better way than to include in a celebration of World Cord Blood Day? In this program, speakers will:
- Review the end to end manufacturing process including collection, processing, testing and storage methods.
- Address current challenges – drop in cord blood utilization, commercial pressures, industry consolidations, and delayed cord clamping.
- Discuss current clinical trials and applications of cord blood.
- Highlight new opportunities - what the future holds for the industry.
This complimentary eCast is part of worldwide celebrations aimed to educate health care professionals and members of the general public on the potential benefits of life-saving cord blood.
Certificate of Attendance & Continuing Education Credits
Continuing education credits and certificates of attendance will
not be provided for this eCast.
Ed Brindle is the Director of Quality & Regulatory Affairs for Insception Biosciences, Canada’s largest cord blood program. Ed Brindle has over 20 years’ experience in quality assurance, Hematology, Transfusion Medicine, Microbiology and Clinical Biochemistry. He is Co-Chair of the AABB Standards and FACT Cord Blood Processing Standards committees. He also serves on the technical working group for Canadian Standards Association Standards for Cord Blood. Ed is currently a member of AABB, CSMLS, CMLTO and ASQ and is a quality auditor for AABB and FACT. He is extremely committed and passionate for maintaining the highest quality standards of compliance within the cord blood and cell therapy industry.
Mike Halpenny has been working in the cellular therapy field for over 20 years, starting his career in a research setting and progressing to working in a regulated manufacturing environment. In 2010, Mike was recruited to oversee the design, development, validation and implementation of the manufacturing process for the Canadian Blood Services’ Cord Blood Bank. Mike is a registered Medical Laboratory Technologist (CMLTO, Canadian Medical Laboratory Technologists of Ontario), has completed a certificate in Quality Management for Healthcare Professionals from the Canadian Healthcare Association, is a member of the AABB CTSCC and has been a FACT inspector since 2000. Mike’s experience includes process development with cord blood, HPC-apheresis and bone marrow production and testing areas. He has had the opportunity to participate and contribute in stem cell research projects on mesenchymal stem cells and endothelial progenitor cells.
Missy Vogelpohl has 38 years of experience as a lab professional with 23 years in the clinical lab and transfusion services and 15 years in the cellular therapy arena at ViaCord, a private cord blood bank. Missy worked for 10 plus years as Quality Manager. She is currently focused on the clinical aspect of the business involving the release, distribution and shipment of cord blood products. Missy is committed to the culture of continuous improvement at ViaCord participating in and leading improvement initiatives.